Comparison of Tyrosinase Antibody, Tyrosinase-related Protein-1 and -2 Antibodies, Melanin-concentrating Hormone Receptor Antibody Levels with Autologous Serum Skin Test and Autologous Plasma Skin Test Results in Patients with Vitiligo

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2021 Aug 11

PMID 34377130

Citations 1

Authors

Abdullah Unal

Hatice Uce Ozkol

Yasemin Bayram

Necmettin Akdeniz

Affiliations

Soon will be listed here.

Abstract

Introduction: Although the exact etiopathogenesis of vitiligo is unknown, the autoimmunity hypothesis is much in evidence. The autologous serum skin test (ASST) and autologous plasma skin test (APST) are methods used in the diagnosis of some autoimmune diseases, which are easy and inexpensive to perform.

Aim: In this study, we investigated whether or not ASST and APST could determine autoimmunity in patients with vitiligo.

Material And Methods: In this study, 30 vitiligo patients presenting to the dermatology outpatient clinic and 30 healthy volunteers without any known autoimmune diseases were included. Antibodies such as tyrosinase, tyrosinase-related protein-1 (TYRP1), tyrosinase-related protein-2 (TYRP2) and melanin-concentrating hormone receptor 1 (MCHR1) antibodies determined to be associated with vitiligo were examined. In addition, the association of these antibodies with the positivity of ASST and APST, which were suggested to be associated with autoimmunity, were examined.

Results: In our study, tyrosinase antibody was found to be significantly higher in vitiligo patients. ASST was positive in 12 (40%) patients with vitiligo and 8 (26.6%) control subjects. APST was positive in 8 (26.6%) of the patients with vitiligo and in 2 (6.6%) of the controls, and there was a significant difference between the groups in terms of APST positivity ( = 0.032). In addition, in our study, a significant correlation was found between TYRP1 antibody positivity and APST positivity in the patient group ( = 0.005).

Conclusions: These findings suggest that we may use APST to investigate the autoimmune etiopathogenesis of vitiligo.

Citing Articles

Melanogenesis and Hypopigmentation: The Case of Vitiligo.

Vinardell M, Maddaleno A, Mitjans M Indian J Dermatol. 2023; 67(5):524-530.

PMID: 36865864 PMC: 9971791. DOI: 10.4103/ijd.ijd_1067_21.

References

Rocha I, Oliveira L, De Castro L, de Araujo Pereira L, Chaul A, Guerra J . Recognition of melanoma cell antigens with antibodies present in sera from patients with vitiligo. Int J Dermatol. 2000; 39(11):840-3. DOI: 10.1046/j.1365-4362.2000.00089.x. View

Ravetch J, Clynes R . Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998; 16:421-32. DOI: 10.1146/annurev.immunol.16.1.421. View

Cui T, Yi X, Zhang W, Wei C, Zhou F, Jian Z . miR-196a-2 rs11614913 polymorphism is associated with vitiligo by affecting heterodimeric molecular complexes of Tyr and Tyrp1. Arch Dermatol Res. 2015; 307(8):683-92. DOI: 10.1007/s00403-015-1563-1. View

Kemp E, Waterman E, Gawkrodger D, Watson P, Weetman A . Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol. 1999; 139(5):798-805. DOI: 10.1046/j.1365-2133.1998.02503.x. View

Huggins R, Schwartz R, Janniger C . Vitiligo. Acta Dermatovenerol Alp Pannonica Adriat. 2006; 14(4):137-42, 144-5. View

Naughton G, Eisinger M, Bystryn J . Antibodies to normal human melanocytes in vitiligo. J Exp Med. 1983; 158(1):246-51. PMC: 2187087. DOI: 10.1084/jem.158.1.246. View

Zamani M, Spaepen M, Sghar S, Huang C, Westerhof W, Nieuweboer-Krobotova L . Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol. 2001; 145(1):90-4. DOI: 10.1046/j.1365-2133.2001.04288.x. View

Kemp E, Gawkrodger D, Watson P, Weetman A . Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol. 1997; 109(3):495-500. PMC: 1904761. DOI: 10.1046/j.1365-2249.1997.4781381.x. View

Farrokhi S, Hojjat-Farsangi M, Noohpisheh M, Tahmasbi R, Rezaei N . Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol. 2005; 19(6):706-11. DOI: 10.1111/j.1468-3083.2005.01295.x. View

10.

Kemp E, Gawkrodger D, Watson P, Weetman A . Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol. 1998; 114(3):333-8. PMC: 1905130. DOI: 10.1046/j.1365-2249.1998.00746.x. View

11.

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N . Vitiligo. Lancet. 2015; 386(9988):74-84. DOI: 10.1016/S0140-6736(14)60763-7. View

12.

Xie Z, Chen D, Jiao D, Bystryn J . Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol. 1999; 135(4):417-22. DOI: 10.1001/archderm.135.4.417. View

13.

Kemp E, Emhemad S, Akhtar S, Watson P, Gawkrodger D, Weetman A . Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol. 2010; 20(1):35-40. DOI: 10.1111/j.1600-0625.2010.01181.x. View

14.

Trcka J, Moroi Y, Clynes R, Goldberg S, Bergtold A, Perales M . Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity. 2002; 16(6):861-8. DOI: 10.1016/s1074-7613(02)00327-8. View

15.

Ongenae K, van Geel N, Naeyaert J . Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003; 16(2):90-100. DOI: 10.1034/j.1600-0749.2003.00023.x. View

16.

Glassman S . Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond). 2010; 120(3):99-120. DOI: 10.1042/CS20090603. View

17.

Kemp E, Gavalas N, Gawkrodger D, Weetman A . Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007; 6(3):138-42. DOI: 10.1016/j.autrev.2006.09.010. View

18.

Gauthier Y, Andre M, Taieb A . A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res. 2003; 16(4):322-32. DOI: 10.1034/j.1600-0749.2003.00070.x. View

19.

Kroon M, Kemp E, Wind B, Krebbers G, Bos J, Gawkrodger D . Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J Eur Acad Dermatol Venereol. 2012; 27(9):1172-5. DOI: 10.1111/j.1468-3083.2012.04501.x. View

20.

Tarle R, Silva de Castro C, Machado do Nascimento L, Mira M . Polymorphism of the E-cadherin gene CDH1 is associated with susceptibility to vitiligo. Exp Dermatol. 2015; 24(4):300-2. DOI: 10.1111/exd.12641. View